XML 44 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Collaborations, License Agreements and Commitments (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Jan. 31, 2020
Service income $ 1,878 $ 419  
Revenues 1,385 419  
Research and development expenses 4,703 $ 5,300  
Image Securities Ltd [Member]      
Related party transferred 500    
Advance from related party 3,000    
Image Securities Ltd [Member] | Master Services Agreement [Member]      
Service income 493    
Hemogenyx Pharmaceuticals PLC. [Member] | Loan Agreement [Member]      
Loans receivable net 250    
Immugenyx LLC [Member] | Loan Agreement [Member]      
Loans receivable net $ 250    
Theracell Advanced Biotechnology [Member]      
Interest in joint venture 50.00%    
Noncontrolling interest in joint venture 50.00%    
Theracell Advanced Biotechnology [Member] | Master Services Agreement [Member]      
Research and development expenses $ 559    
Theracell Advanced Biotechnology [Member] | Master Services Agreement [Member] | Development Service Revenue [Member]      
Revenues 496    
Broaden Bioscience and Technology Corp [Member]      
Research and development expenses 830    
Broaden Bioscience and Technology Corp [Member] | Master Services Agreement [Member] | Development Service Revenue [Member]      
Revenues 488    
Broaden Bioscience and Technology Corp [Member] | Convertible Loan Agreement [Member]      
Loans receivable net     $ 5,000
Cure Therapeutics [Member] | Master Service Agreement [Member] | Development Service Revenue [Member]      
Revenues $ 374    
Mircod Limited [Member]      
Interest in joint venture 50.00%